Serum miR-142-5p serves as a biomarker to predict onset and short-term prognosis in acute coronary syndrome patients

Abstract Objectives The target of this study was to explore the value of miR-142-5p for diagnosis and prognosis in patients with acute coronary syndrome (ACS). Methods RT-qPCR was utilized to investigate serum miR-142-5p in 77 ACS patients, 65 stable angina pectoris (SAP) patients, and 70 healthy volunteers. Receiver Operating Characteristic (ROC) curves were developed to estimate the clinical diagnostic importance of miR-142-5p for ACS. Kaplan-Meier and Cox regression were utilized to estimate the prognostic value of miR-142-5p for the incidence of major adverse cardiovascular events (MACE) during the 6-month post-treatment surveillance period after percutaneous coronary intervention (PCI) in patients with ACS. Results Serum miR-142-5p was significantly higher in ACS patients than in healthy controls (HC) and SAP groups. ROC curve indicated that serum miR-142-5p was effective in distinguishing ACS patients from HC and also distinguishing ACS patients from SAP patients. Pearson correlation coefficients confirmed that miR-142-5p was positively correlated with cardiac troponin I (cTnI, r=0.690) and Gensini score (GS, r=0.734). Furthermore, patients with high miR-142-5p expression had a greater probability of developing MACE after PCI treatment (Log Rank=0.016), which is an independent prognostic biomarker for ACS. Conclusions miR-142-5p expression was significantly elevated in the serum of ACS patients. It not only demonstrates a strong correlation with an elevated risk of MACE following PCI, but also exhibits diagnostic utility and serves as an independent prognostic biomarker. It is a promising biomarker for the diagnosis and prognosis of ACS.